Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-HAD with or without Bortezomib in Relapsed/Refractory Mantle Cell Lymphoma
NCT01449344Phase 3Unknown
- Start
- May 2009
- Primary completion
- Dec 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of bortezomib in mantle cell lymphoma (MCL) (2 arms). Primary endpoints: Time to Treatment Failure and Change from Baseline of diseased nodes and nodal masses at 126 days. Status: unknown.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01449344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01449344.